부산대학교 도서관

Abstract Background Immunotherapy targeting programmed death 1(PD‐1) and its ligand (PD‐L1) has been successful in extensive‐stage small cell lung cancer (ES‐SCLC). However, first‐line PD‐(L)1 inhibitor combined with chemotherapy (immunochemotherapy) versus chemotherapy has not been well studied. Methods Randomized controlled trials had been searched from PubMed, Embase, and the Cochrane Library until December 29, 2022. Randomized effect consistency models were applied for estimating the pooled hazard ratios (HRs) and odds ratios (ORs). Study outcomes included overall response rate (ORR), progression‐free survival (PFS), overall survival (OS), 6‐month and 1‐year disease progression rate, 1‐year and 2‐year mortality rate, and Grade ≥3 adverse events (AEs). Results Six eligible trials with 2600 ES‐SCLC patients were included. Compared with chemotherapy, immunochemotherapy significantly improved ORR (OR 1.32, 95% CI 1.07–1.63; p = 0.01), PFS (HR 0.68, 95% CI 0.58–0.78; p 0.05). Conclusion Compared with chemotherapy, PD‐(L)1 inhibitor plus chemotherapy as first‐line treatment could improve the efficacy and prognosis of ES‐SCLC patients without more serious side effects. However, more research is needed to validate these results.